Emtricitabine And Tenofovir Disoproxil Fumarate
Generic Name: emtricitabine and tenofovir disoproxil fumarate
Brand Names:
Emtricitabine And Tenofovir Disoproxil Fumarate
Emtricitabine and tenofovir disoproxil fumarate is a fixed-dose combination tablet containing emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) for HIV-1 treatment and pre-exposure prophylaxis.
Overview
Emtricitabine and tenofovir disoproxil fumarate is a fixed-dose combination tablet containing emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) for HIV-1 treatment and pre-exposure prophylaxis.
Uses
Indicated for treating HIV-1 infection in adults and pediatric patients (minimum 17 kg weight) as part of combination therapy, and for pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents (minimum 35 kg weight).
Dosage
Standard dosing is one tablet containing 200 mg FTC and 300 mg TDF once daily orally with or without food.
Side Effects
Most common adverse reactions include diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash.
Interactions
Multiple significant interactions documented with protease inhibitors, hepatitis C antivirals, and nephrotoxic agents.
Warnings
BOXED WARNING: Severe hepatitis B exacerbation risk and drug resistance risks with undiagnosed HIV infection. Includes renal impairment concerns, bone loss, and lactic acidosis warnings. Contraindicated in individuals with unknown or positive HIV-1 status for PrEP use.
Frequently Asked Questions
What is Emtricitabine And Tenofovir Disoproxil Fumarate used for?▼
Indicated for treating HIV-1 infection in adults and pediatric patients (minimum 17 kg weight) as part of combination therapy, and for pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents (minimum 35 kg weight).
What are the side effects of Emtricitabine And Tenofovir Disoproxil Fumarate?▼
Most common adverse reactions include diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash.
What are the important warnings for Emtricitabine And Tenofovir Disoproxil Fumarate?▼
BOXED WARNING: Severe hepatitis B exacerbation risk and drug resistance risks with undiagnosed HIV infection. Includes renal impairment concerns, bone loss, and lactic acidosis warnings. Contraindicated in individuals with unknown or positive HIV-1 status for PrEP use.
Related Medications
Anhydrous Citric Acid, Trisodium Citrate Dihydrate, Sodium Phosphate, Monobasic, Monohydrate, Dextrose Monohydrate, And Adenine
anhydrous citric acid, trisodium citrate dihydrate, sodium phosphate, monobasic, monohydrate, dextrose monohydrate, and adenine
Calculi Dissolution Agent [EPC]
11. DESCRIPTION / PRODUCT SPECIFICATIONS 11.1. This blood bag system includes a 16 gauge × 1 1/2 inch (1.60 × 38 mm) needle with needle cover and either a 450 mL or 500 mL (nominal capacity 600 mL) primary collection bag containing 63 mL or 70 mL, respectively, Citrate Phosphate Dextrose Adenine (CPDA-1) anticoagulant. The Triple blood bag set has one integrally attached empty satellite bag (nominal capacity 400 mL) and one empty XT-612 5 day Platelet bag (nominal capacity 500 mL).
Glimepiride
glimepiride
Sulfonylurea [EPC]
11 DESCRIPTION Glimepiride tablets, USP are an oral sulfonylurea that contains the active ingredient glimepiride. Chemically, glimepiride is identified as 1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)urea (C 24 H 34 N 4 O 5 S) with a molecular weight of 490.62. Glimepiride USP is a white or almost white powder and is practically insoluble in water.
Betamethasone Valerate
betamethasone valerate
Betamethasone valerate cream USP 0.1% is a synthetic adrenocorticosteroid for dermatologic use, indicated for relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.